Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,437 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,348)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06765928 | Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT | not yet recruiting | Phase 2 | 73 | Ruijin HospitalOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06758726 | Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen for Patients With Intermediate/Adverse Risk or Persistently Positive MRD AML | not yet recruiting | N/A | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jan 6, 2025 |
| clinicaltrials |
| NCT06643195 | Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia | not yet recruiting | N/A | 358 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06746571 | Role of Cbc Indices in Acute Lymphoblastic Leukemia Patients | not yet recruiting | N/A | 100 | Sohag UniversityOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06721598 | An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative Disorders | not yet recruiting | — | 60 | National Research Center for Hematology, RussiaNETWORK | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06702098 | Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia(iNK-r/r AML) | not yet recruiting | Early Phase 1 | 10 | Guangzhou Ruixin Biotechnological Co., LTDINDUSTRY | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06684509 | Atorvaststin and Cardiotoxicity in Acute Myloid Leukemia | not yet recruiting | Phase 1 / Phase 2 | 46 | Assiut UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06674850 | Systemic Inflammation Response Index and C-Reactive Protein to Albumin Ratio in Acute Lymphoblastic Leukemia | not yet recruiting | — | 36 | Assiut UniversityOTHER | 0 | Nov 5, 2024 | clinicaltrials |
| NCT06672263 | A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia | not yet recruiting | Phase 1 | 120 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06668948 | The Prognostic Role of Fibrinogen to Albumin Ratio in Acute Leukemia Patients | not yet recruiting | — | 90 | Assiut UniversityOTHER | 0 | Nov 1, 2024 | clinicaltrials |
| NCT06658938 | Blinatumomab as Maintenance Therapy in Patients With High-risk B-lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation | not yet recruiting | N/A | 30 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Oct 26, 2024 | clinicaltrials |
| NCT06655519 | An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | not yet recruiting | Phase 1 | 12 | Peking University People's HospitalOTHER | 0 | Oct 23, 2024 | clinicaltrials |
| NCT06652685 | Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia | not yet recruiting | Phase 2 | 218 | Ruijin HospitalOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT06649422 | Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study | not yet recruiting | — | 36 | Shandong UniversityOTHER | 0 | Oct 18, 2024 | clinicaltrials |
| NCT06641024 | Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL | not yet recruiting | Phase 1 | 24 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06631040 | Cell Therapy with Anti-CD19 CAR-NK Cells in Patients with Relapsed or Resistant B-ALL | not yet recruiting | Phase 1 / Phase 2 | 10 | Shahid Beheshti University of Medical SciencesOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06631196 | Jacobson's Progressive Muscle Relaxation Technique on Children With Leukemia Undergoing Chemotherapy.(JPMRT) | not yet recruiting | N/A | 80 | Alexandria UniversityOTHER | 0 | Oct 8, 2024 | clinicaltrials |
| NCT06598384 | VA as Maintenance Therapy Post Allo-HSCT in MDS and AML | not yet recruiting | Phase 2 | 40 | Navy General Hospital, BeijingOTHER | 0 | Oct 1, 2024 | clinicaltrials |
| NCT06613035 | Twice-per-weekSelinexor, 2 Days Melphalan | not yet recruiting | Phase 3 | 126 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06591195 | Distraction As Multimodal Pain Management(DISTRACT) | not yet recruiting | N/A | 126 | Radboud University Medical CenterOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06598969 | TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia(TMLI-MA) | not yet recruiting | Phase 2 | 58 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06602323 | TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia.(TMLI-RI) | not yet recruiting | Phase 2 | 34 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06470841 | CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML | not yet recruiting | Phase 2 | 85 | Navy General Hospital, BeijingOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06557304 | The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China | not yet recruiting | — | 1,000 | Peking University People's HospitalOTHER | 0 | Aug 21, 2024 | clinicaltrials |
| NCT06559644 | Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia | not yet recruiting | Early Phase 1 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06530810 | Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML) | not yet recruiting | Phase 1 | 100 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jul 31, 2024 | clinicaltrials |
| NCT05628623 | Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment(ERASE) | not yet recruiting | Phase 2 | 184 | Eastern Cooperative Oncology GroupNETWORK | 0 | Jul 3, 2024 | clinicaltrials |
| NCT06463327 | ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML(ACHIEVE2) | not yet recruiting | Phase 1 | 69 | TC BiopharmINDUSTRY | 0 | Jun 17, 2024 | clinicaltrials |
| NCT06297772 | Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR | not yet recruiting | Phase 3 | 220 | Ruijin HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06441084 | A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation | not yet recruiting | Phase 1 | 15 | Nuwacell Biotechnologies Co., Ltd.INDUSTRY | 0 | Jun 4, 2024 | clinicaltrials |
| NCT06416267 | Risk and Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis (LC MBL)(MBL RiskConseq) | not yet recruiting | — | 1,500 | University of HaifaOTHER | 0 | May 16, 2024 | clinicaltrials |
| NCT06364033 | Biological and Clinical Efficacy of Shingrix in Patients With CLL | not yet recruiting | N/A | 312 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT05718986 | Familial B-cell Lymphoproliferative Disorders(Familial_LPD) | not yet recruiting | — | 1,000 | University of HaifaOTHER | 0 | May 8, 2024 | clinicaltrials |
| NCT06387420 | A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia | not yet recruiting | Phase 1 / Phase 2 | 180 | AkesoINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT06385808 | Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML | not yet recruiting | N/A | 37 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | Apr 26, 2024 | clinicaltrials |
| NCT06367374 | MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL | not yet recruiting | Phase 2 | 66 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Apr 16, 2024 | clinicaltrials |
| NCT06090786 | Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax | not yet recruiting | N/A | 225 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | Apr 10, 2024 | clinicaltrials |
| NCT05319249 | Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia(NAKIP-AML) | not yet recruiting | Phase 1 / Phase 2 | 54 | German Cancer Research CenterOTHER | 0 | Apr 5, 2024 | clinicaltrials |
| NCT06347458 | BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children | not yet recruiting | Phase 1 | 24 | Guangzhou Bio-gene Technology Co., LtdINDUSTRY | 0 | Apr 4, 2024 | clinicaltrials |
| NCT06295029 | Personalized Medication Software for BCL-2 Inhibitor in AML Patients Using Machine Learning and Genomics | not yet recruiting | — | 200 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Mar 6, 2024 | clinicaltrials |
| NCT06050941 | Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS | not yet recruiting | Phase 2 | 60 | First Affiliated Hospital of Zhejiang UniversityOTHER | 0 | Mar 5, 2024 | clinicaltrials |
| NCT06266975 | Chronic Kidney Disease Patient in Chronic Myloied Leukemia | not yet recruiting | — | 40 | Sahar Mohammed GadOTHER | 0 | Feb 20, 2024 | clinicaltrials |
| NCT06252584 | Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients(AML-VAC-XS15) | not yet recruiting | Phase 1 | 20 | University Hospital TuebingenOTHER | 0 | Feb 9, 2024 | clinicaltrials |
| NCT06242353 | Coagulopathy in Childhood Acute Lymphoblastic Leukaemia(CoagCALL) | not yet recruiting | — | 100 | Karolinska University HospitalOTHER | 0 | Feb 5, 2024 | clinicaltrials |
| NCT06175923 | Role of BMP Pathway in MDS Progression(BMP-MDS) | not yet recruiting | — | 60 | Hospices Civils de LyonOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06175702 | Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL(LALPh2022) | not yet recruiting | — | 150 | PETHEMA FoundationOTHER | 0 | Dec 19, 2023 | clinicaltrials |
| NCT06133556 | Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML | not yet recruiting | Phase 2 | 237 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Nov 15, 2023 | clinicaltrials |
| NCT06075238 | Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT | not yet recruiting | Phase 2 | 68 | Sichuan UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT04790045 | Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens(LymBIO) | not yet recruiting | Phase 4 | 30 | Paolo GhiaOTHER | 0 | Oct 3, 2023 | clinicaltrials |
| NCT05875649 | A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure(CLAG) | not yet recruiting | — | 137 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jan 9, 2025source: clinicaltrials